Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer

Area of Science:

• Oncology
• Medical Genetics
• Pharmacology

Background:

• Lung cancer with brain metastases presents a poor prognosis due to chemotherapy's limited blood-brain barrier penetration.
• Epidermal Growth Factor Receptor (EGFR) mutations, particularly in exons 18-21, are key drivers in certain lung adenocarcinomas.
• Targeted therapies offer potential for improved outcomes in advanced cancer with central nervous system involvement.

Observation:

• A 61-year-old female patient with stage IV lung adenocarcinoma presented with extensive brain and cerebellar metastases.
• The patient's tumor exhibited a specific mutation in exon 19 of the EGFR gene.
• Systemic chemotherapy was ineffective for the central nervous system (CNS) metastases.

Findings:

• Treatment with erlotinib, an EGFR inhibitor, was initiated upon identification of the EGFR mutation.
• The patient experienced a remarkable and complete radiographic response in CNS disease.
• All previously detected brain and cerebellar metastases resolved completely following erlotinib treatment.

Implications:

• Erlotinib demonstrates significant efficacy in treating EGFR-mutated lung cancer with central nervous system metastases.
• This case highlights the potential of targeted therapy to overcome the challenge of the blood-brain barrier in lung cancer.
• Non-invasive treatment with erlotinib may be a viable alternative to radiation for select patients with brain metastases.